TY  - JOUR
AU  - Mack, Stephen C
AU  - Pajtler, Kristian
AU  - Chavez, Lukas
AU  - Okonechnikov, Konstantin
AU  - Bertrand, Kelsey C
AU  - Wang, Xiuxing
AU  - Erkek, Serap
AU  - Federation, Alexander
AU  - Song, Anne
AU  - Lee, Christine
AU  - Wang, Xin
AU  - McDonald, Laura
AU  - Morrow, James J
AU  - Saiakhova, Alina
AU  - Sin-Chan, Patrick
AU  - Wu, Qiulian
AU  - Michaelraj, Kulandaimanuvel Antony
AU  - Miller, Tyler E
AU  - Hubert, Christopher G
AU  - Ryzhova, Marina
AU  - Garzia, Livia
AU  - Donovan, Laura
AU  - Dombrowski, Stephen
AU  - Factor, Daniel C
AU  - Luu, Betty
AU  - Valentim, Claudia L L
AU  - Gimple, Ryan C
AU  - Morton, Andrew
AU  - Kim, Leo
AU  - Prager, Briana C
AU  - Lee, John J Y
AU  - Wu, Xiaochong
AU  - Zuccaro, Jennifer
AU  - Thompson, Yuan
AU  - Holgado, Borja L
AU  - Reimand, Jüri
AU  - Ke, Susan Q
AU  - Tropper, Adam
AU  - Lai, Sisi
AU  - Vijayarajah, Senthuran
AU  - Doan, Sylvia
AU  - Mahadev, Vaidehi
AU  - Miñan, Ana Fernandez
AU  - Gröbner, Susanne
AU  - Lienhard, Matthias
AU  - Zapatka, Marc
AU  - Huang, Zhiqin
AU  - Aldape, Kenneth D
AU  - Carcaboso, Angel M
AU  - Houghton, Peter J
AU  - Keir, Stephen T
AU  - Milde, Till
AU  - Witt, Hendrik
AU  - Li, Yan
AU  - Li, Chao-Jun
AU  - Bian, Xiu-Wu
AU  - Jones, David
AU  - Scott, Ian
AU  - Singh, Sheila K
AU  - Huang, Annie
AU  - Dirks, Peter B
AU  - Bouffet, Eric
AU  - Bradner, James E
AU  - Ramaswamy, Vijay
AU  - Jabado, Nada
AU  - Rutka, James T
AU  - Northcott, Paul A
AU  - Lupien, Mathieu
AU  - Lichter, Peter
AU  - Korshunov, Andrey
AU  - Scacheri, Peter C
AU  - Pfister, Stefan
AU  - Kool, Marcel
AU  - Taylor, Michael D
AU  - Rich, Jeremy N
TI  - Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
JO  - Nature 
VL  - 553
IS  - 7686
SN  - 1476-4687
CY  - London [u.a.]
PB  - Nature Publ. Group
M1  - DKFZ-2018-00087
SP  - 101 - 105
PY  - 2018
AB  - Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy. The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes. More than 70
LB  - PUB:(DE-HGF)16
C6  - pmid:29258295
DO  - DOI:10.1038/nature25169
UR  - https://inrepo02.dkfz.de/record/131790
ER  -